With a trial win in certain acute myeloid leukemia (AML) patients, Servier’s cancer med Tibsovo is primed to break into front-line use as a combo treatment for patients who can't handle intensive ...
The addition of ivosidenib (Tibsovo) to azacitidine led to a threefold survival improvement for newly diagnosed IDH1-mutant acute myeloid leukemia (AML) patients who were ineligible for intensive ...
Tibsovo plus Vidaza led to survival benefit for patients with IDH1-mutant acute myeloid leukemia, according to findings from the AGILE clinical trial. Findings from the phase 3 AGILE trial showed ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results